A U.S. appeals court upholds a lower court ruling in favor of Pozen (POZN -0.8%) against Par...
A U.S. appeals court upholds a lower court ruling in favor of Pozen (POZN -0.8%) against Par Pharmaceutical (PRX), Alphapharm and Dr. Reddy’s Laboratories (RDY +1.9%), affirming the district court's earlier decision that found POZN's patent valid, and blocked PRX and RDY from selling a generic version of POZN's migraine drug Treximet until 2025.
From other sites
at CNBC.com (Dec 17, 2014)
at CNBC.com (Dec 15, 2014)
at CNBC.com (Nov 18, 2014)
at CNBC.com (Nov 10, 2014)
at CNBC.com (Nov 22, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs